公开(公告)号：EP1860119A4

公开(公告)日：2009-04-15

申请号：EP06714335

申请日：2006-02-22

申请人： INST ANTIBODIES CO LTD ,  KUROSAWA YOSHIKAZU

发明人： AKAHORI YASUSHI ,  SUGIOKA ATSUSHI ,  HAYASHI NOBUHIRO ,  TAKASAKI AKIHIKO ,  SUZUKI KAZUHIRO ,  MORITA MIWA ,  KUROSAWA YOSHIKAZU ,  IBA YOSHITAKA ,  SUMITOMO MARIKO ,  TSUTSUMI SUSUMU ,  OGAWA KEIKO ,  MATSUDA KAZUKI ,  MURAMATSU CHIHO ,  TAKAHASHI NOBUHIRO ,  FUJIYAMA SARI ,  AZUMA MASACHIKA ,  UKAI YOSHINORI ,  MORISHITA KAZUHIRO

IPC分类号： C07K16/28 ,  A61K39/00 ,  A61P35/00 ,  C12N1/15 ,  C12N1/19 ,  C12N1/21 ,  C12N5/10 ,  C12N15/09 ,  C12Q1/02 ,  G01N33/15 ,  G01N33/50

CPC分类号： C07K16/303 ,  A61K2039/505 ,  C07K16/2803 ,  C07K2317/52 ,  C07K2317/56 ,  C07K2317/565 ,  C07K2317/622 ,  C07K2317/732 ,  C07K2319/00 ,  G01N33/57426 ,  G01N33/57438

摘要： It is intended to clarify a molecule which is available as a target in treating or diagnosing cancer and utilize the molecule in the medical field or the research field. By treating IgSF4, which has been identified as a molecule specifically expressed in lung cancer cells, with an antibody, an ADCC activity is exerted. Based on this finding, an anti-IgSF4 antibody is provided as a means efficacious in treating cancer, etc.